Cargando…

Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir

We report a case of prolonged shedding of the infective SARS-CoV-2 omicron variant BA.1.1.2 in a 79-year-old male patient with diffuse large B-cell lymphoma, after receiving chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). The patient was admitted t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Kiwamu, Sugiyama, Masahiro, Ishizuka, Hikari, Sasajima, Tomomi, Minakawa, Yoko, Sato, Hiroko, Miyazawa, Masatsugu, Kitakawa, Kazuhiro, Fujita, Shohei, Saito, Nozomi, Kashiwabara, Naoko, Kohata, Hironobu, Hara, Yasuka, Kanari, Yumiko, Shinka, Toshikatsu, Kanemitsu, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176961/
https://www.ncbi.nlm.nih.gov/pubmed/37182841
http://dx.doi.org/10.1016/j.jiac.2023.05.003
_version_ 1785040528674390016
author Nakamura, Kiwamu
Sugiyama, Masahiro
Ishizuka, Hikari
Sasajima, Tomomi
Minakawa, Yoko
Sato, Hiroko
Miyazawa, Masatsugu
Kitakawa, Kazuhiro
Fujita, Shohei
Saito, Nozomi
Kashiwabara, Naoko
Kohata, Hironobu
Hara, Yasuka
Kanari, Yumiko
Shinka, Toshikatsu
Kanemitsu, Keiji
author_facet Nakamura, Kiwamu
Sugiyama, Masahiro
Ishizuka, Hikari
Sasajima, Tomomi
Minakawa, Yoko
Sato, Hiroko
Miyazawa, Masatsugu
Kitakawa, Kazuhiro
Fujita, Shohei
Saito, Nozomi
Kashiwabara, Naoko
Kohata, Hironobu
Hara, Yasuka
Kanari, Yumiko
Shinka, Toshikatsu
Kanemitsu, Keiji
author_sort Nakamura, Kiwamu
collection PubMed
description We report a case of prolonged shedding of the infective SARS-CoV-2 omicron variant BA.1.1.2 in a 79-year-old male patient with diffuse large B-cell lymphoma, after receiving chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). The patient was admitted to our hospital in late March 2022 for the sixth course of R-CHOP chemotherapy. Initially, the patient tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an in-hospital loop-mediated amplification assay with a nasopharyngeal swab, both on the day of admission and three days later. However, the patient developed fever and was diagnosed with coronavirus disease (COVID-19) six days after admission and was suspected to have contracted the infection in the ward. Viral shedding continued for more than three months, with confirmed viral infectivity. As compared to the original Wuhan-Hu-1/2019 strain, amino acid substitutions including S36 N in non-structural protein (NSP)2, S148P, S1265del and L1266I in NSP3, G105D in NSP4, G496S, A831V, or V987F in spike protein, and I45T in open-reading frame (ORF)9b were randomly detected in isolated viruses. Although the patient had received two doses of the BNT162b2 vaccine approximately six months earlier and the third dose on day 127 after the infection, both serum anti-spike and anti-nuclear protein IgG and IgM tests were negative at day 92, 114, and 149 after the infection. The patient finally cleared the virus after the third course of remdesivir and did not have further recurrence.
format Online
Article
Text
id pubmed-10176961
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-101769612023-05-12 Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir Nakamura, Kiwamu Sugiyama, Masahiro Ishizuka, Hikari Sasajima, Tomomi Minakawa, Yoko Sato, Hiroko Miyazawa, Masatsugu Kitakawa, Kazuhiro Fujita, Shohei Saito, Nozomi Kashiwabara, Naoko Kohata, Hironobu Hara, Yasuka Kanari, Yumiko Shinka, Toshikatsu Kanemitsu, Keiji J Infect Chemother Case Report We report a case of prolonged shedding of the infective SARS-CoV-2 omicron variant BA.1.1.2 in a 79-year-old male patient with diffuse large B-cell lymphoma, after receiving chemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). The patient was admitted to our hospital in late March 2022 for the sixth course of R-CHOP chemotherapy. Initially, the patient tested negative for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using an in-hospital loop-mediated amplification assay with a nasopharyngeal swab, both on the day of admission and three days later. However, the patient developed fever and was diagnosed with coronavirus disease (COVID-19) six days after admission and was suspected to have contracted the infection in the ward. Viral shedding continued for more than three months, with confirmed viral infectivity. As compared to the original Wuhan-Hu-1/2019 strain, amino acid substitutions including S36 N in non-structural protein (NSP)2, S148P, S1265del and L1266I in NSP3, G105D in NSP4, G496S, A831V, or V987F in spike protein, and I45T in open-reading frame (ORF)9b were randomly detected in isolated viruses. Although the patient had received two doses of the BNT162b2 vaccine approximately six months earlier and the third dose on day 127 after the infection, both serum anti-spike and anti-nuclear protein IgG and IgM tests were negative at day 92, 114, and 149 after the infection. The patient finally cleared the virus after the third course of remdesivir and did not have further recurrence. Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. 2023-08 2023-05-12 /pmc/articles/PMC10176961/ /pubmed/37182841 http://dx.doi.org/10.1016/j.jiac.2023.05.003 Text en © 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Nakamura, Kiwamu
Sugiyama, Masahiro
Ishizuka, Hikari
Sasajima, Tomomi
Minakawa, Yoko
Sato, Hiroko
Miyazawa, Masatsugu
Kitakawa, Kazuhiro
Fujita, Shohei
Saito, Nozomi
Kashiwabara, Naoko
Kohata, Hironobu
Hara, Yasuka
Kanari, Yumiko
Shinka, Toshikatsu
Kanemitsu, Keiji
Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir
title Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir
title_full Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir
title_fullStr Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir
title_full_unstemmed Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir
title_short Prolonged infective SARS-CoV-2 omicron variant shedding in a patient with diffuse large B cell lymphoma successfully cleared after three courses of remdesivir
title_sort prolonged infective sars-cov-2 omicron variant shedding in a patient with diffuse large b cell lymphoma successfully cleared after three courses of remdesivir
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176961/
https://www.ncbi.nlm.nih.gov/pubmed/37182841
http://dx.doi.org/10.1016/j.jiac.2023.05.003
work_keys_str_mv AT nakamurakiwamu prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT sugiyamamasahiro prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT ishizukahikari prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT sasajimatomomi prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT minakawayoko prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT satohiroko prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT miyazawamasatsugu prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT kitakawakazuhiro prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT fujitashohei prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT saitonozomi prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT kashiwabaranaoko prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT kohatahironobu prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT harayasuka prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT kanariyumiko prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT shinkatoshikatsu prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir
AT kanemitsukeiji prolongedinfectivesarscov2omicronvariantsheddinginapatientwithdiffuselargebcelllymphomasuccessfullyclearedafterthreecoursesofremdesivir